Critical Path Institute

Rare disease cures accelerator-data and analytics platform (rdca-dap) - see schedule o

Cure drug repurposing collaboratory (cdrc) - see schedule o

Critical path institute also executes other projects and consortia in areas including therapeutics for the ataxias, polycystic kidney disorder, alzheimer's disease, parkinson's, tb, sickle cell disease, type 1 diabetes, duchenne muscular dystrophy, alpha-1 antitrypsin deficiency, lysosomal diseases, model informed drug development, patient-reported outcome, electronic clinical outcome assessment, rare disease clinical outcome assessment, transplant therapeutics, predictive safety testing, pediatrics, and others.